Background and Purpose:
The prognosis of patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor, as effective treatment options are limited. The authors performed a retrospective review to evaluate the efficacy of proton-beam therapy (PBT) for patients presenting with PVTT in the setting of HCC.
Patients and Methods:
Between February 1991 and September 2005, 35 patients with HCC and tumor thrombi in the main trunk or major branches of the portal vein presented for consideration of PBT. Their tumor sizes ranged from 25 mm to 130 mm (median, 60 mm). A median total dose of 72.6 GyE in 22 fractions was delivered over 31 days to a target volume that encompassed both the primary hepatic lesion and the PVTT.
Results:
32 patients were progression-free during a median follow-up period of 21 months (range, 2–88 months) and three patients experienced disease progression. Local progression-free survival rates were 46% at 2 years and 20% at 5 years, and the median local progression-free survival was 21 months. Acute toxicity ≥ grade 3 was observed in three patients, and no patient experienced late toxicity ≥ grade 3. None of the patients had to discontinue treatment as a result of toxicity.
Conclusion:
PBT improved local control and significantly prolonged survival in HCC patients with PVTT.
Hintergrund und Ziel:
Die Prognose von Patienten mit fortgeschrittenem hepatozellulären Karzinom (HCC) mit Tumorthrombose der Pfortader ist in Ermangelung effektiver Behandlungsmöglichkeiten äußerst schlecht. In einer retrospektiven Studie untersuchten die Autoren die Wirksamkeit einer Protonenbestrahlung bei Patienten, die an einer durch das HCC verursachten Tumorthrombose der Pfortader litten.
Patienten und Methodik:
Zwischen Februar 1991 und September 2005 stellten sich 35 Patienten mit HCC und Tumorthromben in der Pfortader selbst oder in deren großen Ästen zur Erwägung einer Protonenbestrahlung vor. Die Tumorgröße betrug zwischen 25 mm und 130 mm (median 60 mm). Eine mediane Gesamtdosis von 72,6 GyE wurde in 22 Fraktionen über einen Zeitraum von 31 Tagen im Zielvolumen, das sowohl den Primärtumor als auch die Tumorthrombose in der Pfortader beinhaltete, appliziert.
Ergebnisse:
32 Patienten blieben über einen medianen Nachbeobachtungszeitraum von 21 Monaten progressionsfrei (Spanne 2–88 Monate), drei Patienten erlitten einen Krankheitsprogress. Das lokale progressionsfreie Überleben betrug 46% nach 2 Jahren und 20% nach 5 Jahren, das mediane lokale progressionsfreie Überleben lag bei 21 Monaten. Akuttoxizitäten ≥ Grad 3 wurden bei drei Patienten beobachtet, kein Patient erlitt Spättoxizitäten ≥ Grad 3. Bei keinem Patienten musste die Behandlung infolge von Toxizitäten abgebrochen werden.
Schlussfolgerung:
Die Protonenbestrahlung verbesserte die lokale Kontrolle und führte zu einer signifikanten Verlängerung des Überlebens von Patienten mit HCC und einer Tumorthrombose der Pfortader.
Similar content being viewed by others
References
Allison DJ, Jordan H, Hennessy O. Therapeutic embolisation of the hepatic artery: a review of 75 procedures. Lancet 1985;1:595–599.
Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. Analysis of 48 cases. Cancer 2002;95:588–595.
Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinoma: a retrospective and nationwide survey in Japan. Hepatology 2000;32:1224–1229.
Bekkering GE, Rutjes AW, Vlassov VV, et al. The effectiveness and safety of proton radiation therapy for indications of the eye. A systematic review. Strahlenther Onkol 2009;185:211–221.
Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–285.
Cook GC. Hepatocellular carcinoma: one of the world’s most common malignancies. Q J Med 1985;57:705–708.
Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187–220.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radial Oncol Biol Phys 1995;31:1341–1346.
Del Gaudio M, Grazi GL, Principe A, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004;51:510–514.
Doci R, Bignami P, Bozzetti F, et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988;61:1983–1987.
Eisele RM, Schumacher G, Neuhaus P. Local recurrence following hepatic radiofrequency ablation. Diagnosis and treatment. Strahlenther Onkol 2008;184:598–604.
Georg D, Georg P, Hillbrand M, et al. Assessment of improved organ at risk sparing for advanced cervix carcinoma utilizing precision radiotherapy techniques. Strahlenther Onkol 2008;184:586–591.
Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005;104:794–801.
Hata M, Tokuuye K, Sugahara S, et al. Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites. Technical considerations and results. Strahlenther Onkol 2007;183:411–416.
Horigome H, Nomura T, Nakao H, et al. Treatment of solitary small hepatocellular carcinoma: consideration of hepatic functional reserve and mode of recurrence. Hepatogastroenterology 2000;47:507–511.
Hsu WC, Chan SC, Ting LL, et al. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol 2006;36:93–99.
Ikai I, Yamaoka Y, Yamamoto Y, et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 1998;227:433–439.
Inada T, Hayakawa Y, Ohara K, et al. Treatment planning system for high energy proton beam. Nippon Acta Radiol 1983;43:781–793.
Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189–193.
Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143–148.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
Kumada K, Ozawa K, Okamoto R, et al. Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi. Surgery 1990;108:821–827.
Lee HS, Kin JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997;79:2087–2094.
Lewin K, Millis RR. Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 1973;96:21–26.
Llovet JM, Burroughs A, Bruix I. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225–235.
Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for design and evaluation of therapeutic trials. Hepatology 1999;29:62–67.
McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19:3–23.
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207–214.
Nakagawa K, Yamashita H, Shiraishi K, et al. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005;11:7237–7241.
Obi S, Yoshida H, Toune R, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990–1997.
Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928.
Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005;93:557–564.
Pawarode A, Voravud N, Sriuranpong V, et al. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 1998;21:386–391.
Pech M, Wieners G, Kryza R, et al. CT-guided brachytherapy (CTGB) versus interstitial laser ablation (ILT) of colorectal liver metastases. An intraindividual matched-pair analysis. Strahlenther Onkol 2008;184:302–306.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649.
The Research Group for Population-Based Cancer Registration in Japan in 1995. Estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 2000;30:318–321.
Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 6th edn. New York: Wiley & Sons, 2002.
Tanaka N, Matsuzaki Y, Chugangi Y, et al. Proton irradiation for hepatocellular carcinoma. Lancet 1992;340:1358.
Timmermann B, Lomax AJ, Nobile L, et al. Novel technique of craniospinal axis proton therapy with the spot-scanning system. Avoidance of patching multiple fields and optimized ventral dose distribution. Strahlenther Onkol 2007;183:685–688.
Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233–238.
Wang C, Nakayama H, Sugahara S, et al. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal X-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol 2009;185:231–234.
Wharton JT, Delclos L, Gallager S, et al. Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 1973;117:73–80.
Yamada A, Sato M, Kawabata M, et al. Hepatic artery embolisation in 120 patients with unresectable hepatoma. Radiology 1983;148:397–401.
Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8–24.
Zeng ZC, Fan J, Tang ZY, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432–443.
Author information
Authors and Affiliations
Corresponding author
Additional information
*Presented in part at the 27th Annual Scientific Meeting of the European Society for Therapeutic Radiology Oncology (ESTRO), September 14–18, 2008, Gothenburg, Sweden.
Rights and permissions
About this article
Cite this article
Sugahara, S., Nakayama, H., Fukuda, K. et al. Proton-Beam Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis*. Strahlenther Onkol 185, 782–788 (2009). https://doi.org/10.1007/s00066-009-2020-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-009-2020-x